{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T08:04:03Z","timestamp":1784707443753,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chang Gung Memorial Hospital Research Project","award":["CGRPG8N0011"],"award-info":[{"award-number":["CGRPG8N0011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00066-025-02495-9","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:17:27Z","timestamp":1764566247000},"page":"852-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proton beam therapy versus trans-arterial chemoembolization for BCLC stage\u00a0B hepatocellular carcinoma\u2014a\u00a0propensity-matched analysis"],"prefix":"10.1007","volume":"202","author":[{"given":"Tzu-ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Shen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-Yen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-You","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Shih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5080-0394","authenticated-orcid":false,"given":"Jen-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"2","key":"2495_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal\u00a0AG, Lampertico\u00a0P, Nahon\u00a0P (2020) Epidemiology and surveillance for hepatocellular carcinoma: new trends. J\u00a0Hepatol 72(2):250\u2013261. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.025","journal-title":"J Hepatol"},{"issue":"2","key":"2495_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero\u00a0JA, Kulik\u00a0LM, Sirlin\u00a0CB et\u00a0al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68(2):723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913","journal-title":"Hepatology"},{"issue":"2","key":"2495_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet\u00a0JM, Bruix\u00a0J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429\u2013442. https:\/\/doi.org\/10.1053\/jhep.2003.50047","journal-title":"Hepatology"},{"issue":"5","key":"2495_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo\u00a0CM, Ngan\u00a0H, Tso\u00a0WK et\u00a0al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171. https:\/\/doi.org\/10.1053\/jhep.2002.33156","journal-title":"Hepatology"},{"issue":"9319","key":"2495_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/s0140-6736(02)08649-x","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet\u00a0JM, Real\u00a0MI, Monta\u00f1a\u00a0X et\u00a0al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a\u00a0randomised controlled trial. Lancet 359(9319):1734\u20131739. https:\/\/doi.org\/10.1016\/s0140-6736(02)08649-x","journal-title":"Lancet"},{"key":"2495_CR6","doi-asserted-by":"publisher","first-page":"110223","DOI":"10.1016\/j.radonc.2024.110223","volume":"194","author":"F Liu","year":"2024","unstructured":"Liu\u00a0F, Brown\u00a0DR, Munley\u00a0MT (2024) Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma. Radiother Oncol 194:110223. https:\/\/doi.org\/10.1016\/j.radonc.2024.110223","journal-title":"Radiother Oncol"},{"issue":"4","key":"2495_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.semradonc.2017.04.002","volume":"27","author":"P Munoz-Schuffenegger","year":"2017","unstructured":"Munoz-Schuffenegger\u00a0P, Ng\u00a0S, Dawson\u00a0LA (2017) Radiation-induced liver toxicity. Semin Radiat Oncol 27(4):350\u2013357. https:\/\/doi.org\/10.1016\/j.semradonc.2017.04.002","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2495_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.semradonc.2018.06.007","volume":"28","author":"EJ Koay","year":"2018","unstructured":"Koay\u00a0EJ, Owen\u00a0D, Das\u00a0P (2018) Radiation-induced liver disease and modern radiotherapy. Semin Radiat Oncol 28(4):321\u2013331. https:\/\/doi.org\/10.1016\/j.semradonc.2018.06.007","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2495_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.semradonc.2018.06.005","volume":"28","author":"Y Yu","year":"2018","unstructured":"Yu\u00a0Y, Feng\u00a0M (2018) Radiotherapy for hepatocellular carcinoma. Semin Radiat Oncol 28(4):277\u2013287. https:\/\/doi.org\/10.1016\/j.semradonc.2018.06.005","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"2495_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.meddos.2007.04.008","volume":"33","author":"X Wang","year":"2008","unstructured":"Wang\u00a0X, Krishnan\u00a0S, Zhang\u00a0X et\u00a0al (2008) Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim 33(4):259\u2013267. https:\/\/doi.org\/10.1016\/j.meddos.2007.04.008","journal-title":"Med Dosim"},{"issue":"9","key":"2495_CR11","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1200\/jco.2005.00.620","volume":"23","author":"M Kawashima","year":"2005","unstructured":"Kawashima\u00a0M, Furuse\u00a0J, Nishio\u00a0T et\u00a0al (2005) Phase\u00a0II study of radiotherapy employing proton beam for hepatocellular carcinoma. J\u00a0Clin Oncol 23(9):1839\u20131846. https:\/\/doi.org\/10.1200\/jco.2005.00.620","journal-title":"J Clin Oncol"},{"issue":"3","key":"2495_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ijrobp.2008.10.073","volume":"74","author":"N Fukumitsu","year":"2009","unstructured":"Fukumitsu\u00a0N, Sugahara\u00a0S, Nakayama\u00a0H et\u00a0al (2009) A\u00a0prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 74(3):831\u2013836. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.073","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2495_CR13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/jco.2015.64.2710","volume":"34","author":"TS Hong","year":"2016","unstructured":"Hong\u00a0TS, Wo\u00a0JY, Yeap\u00a0BY et\u00a0al (2016) Multi-institutional phase\u00a0II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and Intrahepatic cholangiocarcinoma. J\u00a0Clin Oncol 34(5):460\u2013468. https:\/\/doi.org\/10.1200\/jco.2015.64.2710","journal-title":"J Clin Oncol"},{"issue":"1","key":"2495_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13014-020-01605-4","volume":"15","author":"JY Cheng","year":"2020","unstructured":"Cheng\u00a0JY, Liu\u00a0CM, Wang\u00a0YM et\u00a0al (2020) Proton versus photon radiotherapy for primary hepatocellular carcinoma: a\u00a0propensity-matched analysis. Radiat Oncol 15(1):159. https:\/\/doi.org\/10.1186\/s13014-020-01605-4","journal-title":"Radiat Oncol"},{"issue":"1","key":"2495_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","volume":"105","author":"NN Sanford","year":"2019","unstructured":"Sanford\u00a0NN, Pursley\u00a0J, Noe\u00a0B et\u00a0al (2019) Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival. Int J Radiat Oncol Biol Phys 105(1):64\u201372. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.076","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2495_CR16","unstructured":"Taiwan cancer registry work. http:\/\/tcr.cph.ntu.edu.tw\/. Accessed 25 Dec 2023"},{"issue":"3","key":"2495_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig\u00a0M, Forner\u00a0A, Rimola\u00a0J et\u00a0al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J\u00a0Hepatol 76(3):681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"2495_CR18","unstructured":"Taiwan registration cancer center No.108006. https:\/\/twcr.tw\/?p=2155"},{"issue":"4","key":"2495_CR19","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ijrobp.2010.07.015","volume":"81","author":"M Mizumoto","year":"2011","unstructured":"Mizumoto\u00a0M, Okumura\u00a0T, Hashimoto\u00a0T et\u00a0al (2011) Proton beam therapy for hepatocellular carcinoma: a\u00a0comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81(4):1039\u20131045. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.07.015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2495_CR20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson\u00a0PJ, Berhane\u00a0S, Kagebayashi\u00a0C et\u00a0al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a\u00a0new evidence-based approach-the ALBI grade. J\u00a0Clin Oncol 33(6):550\u2013558. https:\/\/doi.org\/10.1200\/JCO.2014.57.9151","journal-title":"J Clin Oncol"},{"issue":"3","key":"2495_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000507370","volume":"9","author":"M Kudo","year":"2020","unstructured":"Kudo\u00a0M, Han\u00a0KH, Ye\u00a0SL et\u00a0al (2020) A\u00a0changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements. Liver Cancer 9(3):245\u2013260. https:\/\/doi.org\/10.1159\/000507370","journal-title":"Liver Cancer"},{"issue":"6","key":"2495_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000480208","volume":"35","author":"T Arizumi","year":"2017","unstructured":"Arizumi\u00a0T, Minami\u00a0T, Chishina\u00a0H et\u00a0al (2017) Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2. Dig Dis 35(6):589\u2013597. https:\/\/doi.org\/10.1159\/000480208","journal-title":"Dig Dis"},{"issue":"22","key":"2495_CR23","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1002\/cncr.34965","volume":"129","author":"DA Bush","year":"2023","unstructured":"Bush\u00a0DA, Volk\u00a0M, Smith\u00a0JC et\u00a0al (2023) Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a\u00a0randomized clinical trial. Cancer 129(22):3554\u20133563. https:\/\/doi.org\/10.1002\/cncr.34965","journal-title":"Cancer"},{"issue":"2","key":"2495_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijrobp.2019.05.066","volume":"105","author":"PC Shen","year":"2019","unstructured":"Shen\u00a0PC, Chang\u00a0WC, Lo\u00a0CH et\u00a0al (2019) Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 105(2):307\u2013318. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.05.066","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2495_CR25","doi-asserted-by":"publisher","first-page":"640461","DOI":"10.3389\/fonc.2021.640461","volume":"11","author":"C Jiang","year":"2021","unstructured":"Jiang\u00a0C, Jing\u00a0S, Zhou\u00a0H et\u00a0al (2021) Efficacy and prognostic factors of trans-arterial chemoembolization combined with stereotactic body radiation therapy for BCLC stage\u00a0B hepatocellular carcinoma. Front Oncol 11:640461. https:\/\/doi.org\/10.3389\/fonc.2021.640461","journal-title":"Front Oncol"},{"issue":"2","key":"2495_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang\u00a0CL, Chiu\u00a0KWH, Chan\u00a0KSK et\u00a0al (2023) Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a\u00a0single-arm, phase\u00a02\u00a0trial. Lancet Gastroenterol Hepatol 8(2):169\u2013178. https:\/\/doi.org\/10.1016\/s2468-1253(22)00339-9","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2495_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro\u00a0V, Llovet\u00a0JM, Miceli\u00a0R et\u00a0al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a\u00a0retrospective, exploratory analysis. Lancet Oncol 10(1):35\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(08)70284-5","journal-title":"Lancet Oncol"},{"issue":"4","key":"2495_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0032-1329906","volume":"32","author":"L Bolondi","year":"2012","unstructured":"Bolondi\u00a0L, Burroughs\u00a0A, Dufour\u00a0JF et\u00a0al (2012) Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a\u00a0subclassification to facilitate treatment decisions. Semin Liver Dis 32(4):348\u2013359. https:\/\/doi.org\/10.1055\/s-0032-1329906","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2495_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000517393","volume":"10","author":"YW Hung","year":"2021","unstructured":"Hung\u00a0YW, Lee\u00a0IC, Chi\u00a0CT et\u00a0al (2021) Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria. Liver Cancer 10(6):629\u2013640. https:\/\/doi.org\/10.1159\/000517393","journal-title":"Liver Cancer"},{"issue":"9","key":"2495_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ciresp.2018.06.004","volume":"96","author":"A Marcacuzco Quinto","year":"2018","unstructured":"Marcacuzco Quinto\u00a0A, Nutu\u00a0OA, San Roman Manso\u00a0R et\u00a0al (2018) Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. Cir Esp 96(9):560\u2013567. https:\/\/doi.org\/10.1016\/j.ciresp.2018.06.004","journal-title":"Cir Esp"},{"issue":"8","key":"2495_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","volume":"10","author":"W Fan","year":"2024","unstructured":"Fan\u00a0W, Zhu\u00a0B, Chen\u00a0S et\u00a0al (2024) Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE vs TACE alone randomized clinical trial. JAMA Oncol 10(8):1047\u20131054. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1831","journal-title":"JAMA Oncol"},{"issue":"10474","key":"2495_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo\u00a0M, Ren\u00a0Z, Guo\u00a0Y et\u00a0al (2025) Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a\u00a0multicentre, randomised, double-blind, phase\u00a03\u00a0study. Lancet 405(10474):203\u2013215. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3","journal-title":"Lancet"},{"issue":"10474","key":"2495_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro\u00a0B, Kudo\u00a0M, Erinjeri\u00a0JP et\u00a0al (2025) Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a\u00a0multiregional, randomised, double-blind, placebo-controlled, phase\u00a03\u00a0study. Lancet 405(10474):216\u2013232. https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0","journal-title":"Lancet"},{"issue":"7","key":"2495_CR34","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1093\/oncolo\/oyae048","volume":"29","author":"CW Su","year":"2024","unstructured":"Su\u00a0CW, Teng\u00a0W, Shen\u00a0EY et\u00a0al (2024) Concurrent atezolizumab plus bevacizumab and high-dose external beam radiotherapy for highly advanced hepatocellular carcinoma. Oncologist 29(7):e922\u2013e31. https:\/\/doi.org\/10.1093\/oncolo\/oyae048","journal-title":"Oncologist"},{"issue":"3","key":"2495_CR35","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.21873\/anticanres.16284","volume":"43","author":"J-Y Cheng","year":"2023","unstructured":"Cheng\u00a0J\u2011Y, Huang\u00a0B\u2011S, Chen\u00a0Y\u2011Y, Wang\u00a0C\u2011C, Chen\u00a0Y\u2011H (2023) Combination of lenvatinib and proton beam therapy in the management of patients with advanced hepatocellular carcinoma. Anticancer Res 43(3):1361\u20131371. https:\/\/doi.org\/10.21873\/anticanres.16284","journal-title":"Anticancer Res"},{"issue":"5","key":"2495_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000526163","volume":"11","author":"M Kudo","year":"2022","unstructured":"Kudo\u00a0M (2022) Atezolizumab plus bevacizumab followed by curative conversion (ABC conversion) in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma. Liver Cancer 11(5):399\u2013406. https:\/\/doi.org\/10.1159\/000526163","journal-title":"Liver Cancer"},{"issue":"1","key":"2495_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21037\/hbsn-21-379","volume":"11","author":"CL Chen","year":"2022","unstructured":"Chen\u00a0CL, Ong\u00a0AD, Cheng\u00a0JY et\u00a0al (2022) Proton beam therapy to bridge or downstage locally advanced hepatocellular carcinoma to living donor liver transplantation. Hepatobiliary Surg Nutr 11(1):103\u2013111. https:\/\/doi.org\/10.21037\/hbsn-21-379","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"6","key":"2495_CR38","doi-asserted-by":"publisher","first-page":"966","DOI":"10.21037\/hbsn-23-410","volume":"12","author":"CL Chen","year":"2023","unstructured":"Chen\u00a0CL, Dungca\u00a0LBP, Yong\u00a0CC et\u00a0al (2023) Proton beam therapy for downstaging hepatocellular carcinoma with lobar portal vein tumor thrombosis to living donor liver transplantation. Hepatobiliary Surg Nutr 12(6):966\u2013974. https:\/\/doi.org\/10.21037\/hbsn-23-410","journal-title":"Hepatobiliary Surg Nutr"}],"updated-by":[{"DOI":"10.1007\/s00066-026-02505-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000}}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02495-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02495-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02495-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:53:38Z","timestamp":1784706818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02495-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02495-9","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In Fig. 2 of this article, the figure panels a and b were swapped.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00066-026-02505-4","URL":"https:\/\/doi.org\/10.1007\/s00066-026-02505-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.-t.\u00a0Liu, B.-S.\u00a0Huang, Y.-M.\u00a0Wang, C.-M.\u00a0Liu, E.-Y.\u00a0Huang, H.-Y.\u00a0Ou, T.-H.\u00a0Hu, S.-N.\u00a0Lu, C.-H.\u00a0Hung, Y.-H.\u00a0Chen, C.-S.\u00a0Chen andC.\u00a0J.-Y.\u00a0Cheng declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Institutional Review Boards of the Chang Gung Medical Foundation in Taoyuan, Taiwan, approval number: 202201875B0. The review board waived signed informed consent owing to the study\u2019s retrospective nature.","order":2,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}